Apollo minority investment to accelerate vVARDIS’s global rollout of Curodont

Introduction / background

ZUG, Switzerland — vVARDIS, the privately held Swiss medical‑technology company behind the peptide‑based Curodont technology for non‑invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that the transaction places vVARDIS’s valuation above US$1.0 billion (€853.3 million), a threshold frequently referred to as “unicorn” status. Financial terms were not disclosed; the founders and co‑CEOs, Drs Haley and Goly Abivardi, will retain a substantial majority shareholding.

What was announced and performed

The Apollo transaction is intended to support vVARDIS’s next phase of global commercial expansion and continued rollout of its Curodont product line. vVARDIS has been introducing one of its principal products, Curodont Repair Fluoride Plus, in the US market under an exclusive distribution agreement with Henry Schein. The company positioned the investment as a means to strengthen commercial infrastructure across key markets in the US and Europe.

Key findings and company data

• Valuation: vVARDIS reported a post‑transaction valuation of more than US$1.0 billion (€853.3 million).*
• Distribution and uptake in the US: Curodont Repair Fluoride Plus has been rolled out in the US since early 2024 through Henry Schein as exclusive distributor. vVARDIS states the product has been used to treat approximately three million teeth and is now present in nearly 20% of US general dental practices.
• Recent financing history: vVARDIS previously secured US$35 million from OrbiMed in February 2025 and an additional US$50 million from OrbiMed in July 2025.
• Transaction structure: Apollo’s funds took a strategic minority position; the founders remain majority shareholders. Specific financial details of the Apollo investment were not released.

Representative statements

Jeremy Honeth, partner at Apollo: “Drs Haley and Goly Abivardi had pioneered ‘a new category in dental care’, backed by peer‑reviewed clinical studies, and built vVARDIS into ‘a differentiated business’. Apollo’s investment supports the company’s continued expansion in key markets across the US and Europe, bringing this restorative therapy to more practices and patients worldwide.”

Dr Haley Abivardi: “Curodont fills a longstanding gap in dentistry: when prevention fails, dentists now have a quick, easy‑to‑use non‑invasive treatment. The rapid adoption of Curodont reflects the urgency of that unmet need. Apollo’s investment will strengthen our commercial foundation in the US and Europe and will enable us to scale this environmentally sustainable technology across markets.”

Dr Goly Abivardi: “Our mission is to bring a medical, science‑driven approach to dentistry. Using peptide‑containing formulations, our non‑invasive technology is an innovative treatment designed to treat caries without drilling and without polymer materials. Apollo’s investment reinforces our leadership in generative dentistry and advances the future of oral science.”

Relevance for dental practice

For clinicians, the announcement signals continued commercial backing for a non‑invasive, peptide‑based approach to managing early carious lesions. In the US, Curodont Repair Fluoride Plus is already distributed exclusively through Henry Schein and, according to vVARDIS, has seen measurable uptake across general practices. The investment may accelerate wider availability and commercial support, but clinical adoption should continue to be guided by peer‑reviewed evidence and individual practice protocols.

Limitations and context

• The company’s valuation figure was provided by vVARDIS and the conversion to euros is noted as calculated on the OANDA platform for 27 April 2026.
• Detailed financial terms of the Apollo minority investment were not disclosed.
• Statements regarding product use and market penetration are reported by the company; independent verification is not provided in the announcement.

SOURCE

https://www.dental-tribune.com/news/apollo-investment-supports-vvardiss-global-curodont-expansion/